Therapeutic vaccine-mediated Gag-specific CD8

Acquired Immunodeficiency Syndrome / immunology Animals Anti-Retroviral Agents / pharmacology CD8-Positive T-Lymphocytes / drug effects Disease Models, Animal Gene Products, gag / immunology Gene Products, vif / immunology Humans Immunogenicity, Vaccine Macaca mulatta SAIDS Vaccines / administration & dosage Simian Acquired Immunodeficiency Syndrome / immunology Simian Immunodeficiency Virus / immunology Viral Load / drug effects

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 07 2020
Historique:
received: 21 02 2020
accepted: 23 06 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 22 12 2020
Statut: epublish

Résumé

Anti-retroviral therapy (ART) can inhibit HIV proliferation but not achieve virus eradication from HIV-infected individuals. Under ART-based HIV control, virus-specific CD8

Identifiants

DOI: 10.1038/s41598-020-68267-w PMID: 32647227 PMC: PMC7347614
pubmed: 32647227
doi: 10.1038/s41598-020-68267-w
pii: 10.1038/s41598-020-68267-w
pmc: PMC7347614
doi:

Substances chimiques

Anti-Retroviral Agents 0
Gene Products, gag 0
Gene Products, vif 0
SAIDS Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11394

Références

Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295. https://doi.org/10.1126/science.278.5341.1291 (1997).
doi: 10.1126/science.278.5341.1291 pubmed: 9360926
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300. https://doi.org/10.1126/science.278.5341.1295 (1997).
doi: 10.1126/science.278.5341.1295 pubmed: 9360927
Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105, 3879–3884. https://doi.org/10.1073/pnas.0800050105 (2008).
doi: 10.1073/pnas.0800050105 pubmed: 18332425
Hatano, H. et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24, 2535–2539. https://doi.org/10.1097/QAD.0b013e32833dba03 (2010).
doi: 10.1097/QAD.0b013e32833dba03 pubmed: 20651585 pmcid: 2954261
Neuhaus, J. et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201, 1788–1795. https://doi.org/10.1086/652749 (2010).
doi: 10.1086/652749 pubmed: 20446848 pmcid: 2872049
Lederman, M. M. et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204, 1217–1226. https://doi.org/10.1093/infdis/jir507 (2011).
doi: 10.1093/infdis/jir507 pubmed: 21917895 pmcid: 3218674
Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010. https://doi.org/10.1371/journal.ppat.1004010 (2014).
doi: 10.1371/journal.ppat.1004010 pubmed: 24651464 pmcid: 3961343
Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51–56. https://doi.org/10.1038/nature16933 (2016).
doi: 10.1038/nature16933 pubmed: 26814962 pmcid: 4865637
Zicari, S. et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses 11, 200. https://doi.org/10.3390/v11030200 (2019).
doi: 10.3390/v11030200 pmcid: 6466530
Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).
doi: 10.1128/JVI.68.7.4650-4655.1994
Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103–6110 (1994).
doi: 10.1128/JVI.68.9.6103-6110.1994
Matano, T. et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72, 164–169 (1998).
doi: 10.1128/JVI.72.1.164-169.1998
Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860. https://doi.org/10.1126/science.283.5403.857 (1999).
doi: 10.1126/science.283.5403.857 pubmed: 9933172
Goulder, P. J. & Watkins, D. I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8, 619–630. https://doi.org/10.1038/nri2357 (2008).
doi: 10.1038/nri2357 pubmed: 18617886 pmcid: 2963026
Dalod, M. et al. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein–Barr virus responses and changes during antiretroviral therapy. J. Virol. 73, 7108–7116 (1999).
doi: 10.1128/JVI.73.9.7108-7116.1999
Addo, M. M. et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77, 2081–2092. https://doi.org/10.1128/jvi.77.3.2081-2092.2003 (2003).
doi: 10.1128/jvi.77.3.2081-2092.2003 pubmed: 12525643 pmcid: 140965
Kinloch-deLoes, S. et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 192, 607–617. https://doi.org/10.1086/432002 (2005).
doi: 10.1086/432002
Autran, B. et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22, 1313–1322. https://doi.org/10.1097/QAD.0b013e3282fdce94 (2008).
doi: 10.1097/QAD.0b013e3282fdce94 pubmed: 18580611
García, F. et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5, 166ra2. https://doi.org/10.1126/scitranslmed.3004682 (2013).
doi: 10.1126/scitranslmed.3004682 pubmed: 23283367
Pollard, R. B. et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 14, 291–300. https://doi.org/10.1016/S1473-3099(13)70343-8 (2014).
doi: 10.1016/S1473-3099(13)70343-8 pubmed: 24525316
Kiepiela, P. et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46–53. https://doi.org/10.1038/nm1520 (2007).
doi: 10.1038/nm1520 pubmed: 17173051
Streeck, H. et al. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81, 7725–7731. https://doi.org/10.1128/JVI.00708-07 (2007).
doi: 10.1128/JVI.00708-07 pubmed: 17494064 pmcid: 1933382
Schneidewind, A. et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81, 12382–12393. https://doi.org/10.1128/JVI.01543-07 (2007).
doi: 10.1128/JVI.01543-07 pubmed: 17804494 pmcid: 2169010
Kawada, M. et al. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J. Virol. 82, 10199–10206. https://doi.org/10.1128/JVI.01103-08 (2008).
doi: 10.1128/JVI.01103-08 pubmed: 18667518 pmcid: 2566295
Miura, T. et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 83, 2743–2755. https://doi.org/10.1128/JVI.02265-08 (2009).
doi: 10.1128/JVI.02265-08 pubmed: 19116253
Julg, B. et al. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 84, 5540–5549. https://doi.org/10.1128/JVI.02031-09 (2010).
doi: 10.1128/JVI.02031-09 pubmed: 20335261 pmcid: 2876607
Mudd, P. A. et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491, 129–133. https://doi.org/10.1038/nature11443 (2012).
doi: 10.1038/nature11443 pubmed: 23023123
Iwamoto, N. et al. Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells. J. Virol. 88, 425–433. https://doi.org/10.1128/JVI.02634-13 (2014).
doi: 10.1128/JVI.02634-13 pubmed: 24155398 pmcid: 3911762
Takeda, A. et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Virol. 77, 9710–9715. https://doi.org/10.1128/jvi.77.17.9710-9715.2003 (2003).
doi: 10.1128/jvi.77.17.9710-9715.2003 pubmed: 12915583 pmcid: 187428
Matano, T. et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199, 1709–1718. https://doi.org/10.1084/jem.20040432 (2004).
doi: 10.1084/jem.20040432 pubmed: 15210746 pmcid: 2212812
Nyombayire, J. et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus-vectored HIV type 1 Gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis. 215, 95–104. https://doi.org/10.1093/infdis/jiw500 (2017).
doi: 10.1093/infdis/jiw500 pubmed: 28077588
Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287. https://doi.org/10.1038/nature20583 (2016).
doi: 10.1038/nature20583 pubmed: 27841870 pmcid: 5145754
Virnik, K. et al. Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. PLoS ONE 15, e0228163. https://doi.org/10.1371/journal.pone.0228163 (2020).
doi: 10.1371/journal.pone.0228163 pubmed: 32130229 pmcid: 7055890
O’Connor, D. H. et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8, 493–499. https://doi.org/10.1038/nm0502-493 (2002).
doi: 10.1038/nm0502-493 pubmed: 11984594
Naruse, T. K. et al. Diversity of MHC class I genes in Burmese-origin rhesus macaques. Immunogenetics 62, 601–611. https://doi.org/10.1007/s00251-010-0462-z (2010).
doi: 10.1007/s00251-010-0462-z pubmed: 20640416
Nakamura, M. et al. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses during primary simian immunodeficiency virus infection in Burmese rhesus macaques. Microbiol. Immunol. 55, 768–773. https://doi.org/10.1111/j.1348-0421.2011.00384.x (2011).
doi: 10.1111/j.1348-0421.2011.00384.x pubmed: 21895748
Nomura, T. et al. Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in Burmese rhesus macaques. J. Virol. 86, 6481–6490. https://doi.org/10.1128/JVI.07077-11 (2012).
doi: 10.1128/JVI.07077-11 pubmed: 22491464 pmcid: 3393527
Kestler, H. W. 3rd. et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651–662. https://doi.org/10.1016/0092-8674(91)90097-i (1991).
doi: 10.1016/0092-8674(91)90097-i pubmed: 2032289
Horiike, M. et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 423, 107–118. https://doi.org/10.1016/j.virol.2011.11.024 (2012).
doi: 10.1016/j.virol.2011.11.024 pubmed: 22196013
Yamamoto, H., Kawada, M., Takeda, A., Igarashi, H. & Matano, T. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2, e540. https://doi.org/10.1371/journal.pone.0000540 (2007).
doi: 10.1371/journal.pone.0000540 pubmed: 17579714 pmcid: 1890307
Ishii, H. et al. Association of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8
doi: 10.1038/srep30153
Ishii, H. et al. A novel immunogen selectively eliciting CD8
doi: 10.1128/JVI.01876-19 pubmed: 32132238

Auteurs

Midori Nakamura-Hoshi (M)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.
The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Yusuke Takahara (Y)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.
The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Saori Matsuoka (S)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Hiroshi Ishii (H)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Sayuri Seki (S)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Takushi Nomura (T)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Hiroyuki Yamamoto (H)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Hiromi Sakawaki (H)

Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Tomoyuki Miura (T)

Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Tsuyoshi Tokusumi (T)

ID Pharma Co., Ltd., 6 Ohkubo, Tsukuba, Ibaraki, 300-2611, Japan.

Tsugumine Shu (T)

ID Pharma Co., Ltd., 6 Ohkubo, Tsukuba, Ibaraki, 300-2611, Japan.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan. tmatano@nih.go.jp.
The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. tmatano@nih.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Syndrome d'immunodéficience acquise › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Eucaryotes › Animaux › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines nucléocapside › Protéines du core viral › Produits du gène gag › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales régulatrices ou accessoires › Produits du gène vif › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Phénomènes du système immunitaire › Immunogénicité des vaccins › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre le SIDA simien › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Maladies de l'animal › Maladies des primates › Maladies des singes › Syndrome d'immunodéficience acquise du singe › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Rétrovirus simiens › Virus de l'immunodéficience simienne › Therapeutic vaccine-mediated Gag-specific CD8
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Charge virale › Therapeutic vaccine-mediated Gag-specific CD8